Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Preetesh Jain

Showing results (61-70 of 176) with videos related to

Pageof 18
Sort By:
Clinical Lymphoma, Myeloma & Leukemia|June 15, 2013
Sequential lymphomas or clonally unrelated richter syndrome of chronic lymphocytic leukemia into mantle cell lymphomaPreetesh Jain, Xiuning Le, Ken H Young, et al.
American Journal of Nuclear Medicine and Molecular Imaging|September 13, 2021
Computer-aided detection of mantle cell lymphoma on <sup>18</sup>F-FDG PET/CT using a deep learning convolutional neural networkZijian Zhou, Preetesh Jain, Yang Lu, et al.
American Journal of Hematology|June 25, 2016
Mixed angioinvasive exserohilum and scedosporium infection in a patient with AMLPreetesh Jain, Priyadharsini Nagarajan, Parikshit Prayag, et al.
Haematologica|April 11, 2020
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphomaLifu Wang, Guilin Tang, L Jeffrey Medeiros, et al.
American Journal of Hematology|September 28, 2016
PET-positive lymphadenopathy in CLL-Not always Richter transformationNaveen Pemmaraju, Preetesh Jain, L Jeffrey Medeiros, et al.
Blood|January 10, 2015
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinibPreetesh Jain, Michael Keating, William Wierda, et al.
Cancer|February 8, 2017
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinibPreetesh Jain, Philip A Thompson, Michael Keating, et al.
Blood Cancer Journal|February 16, 2023
Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutationsYuxuan Che, Yang Liu, Yixin Yao, et al.
Human Pathology|March 9, 2024
TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are presentDo Hwan Kim, Saima Siddiqui, Preetesh Jain, et al.
Blood Cancer Journal|April 8, 2026
Correction: Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutationsYuxuan Che, Yang Liu, Yixin Yao, et al.
Pageof 18

Showing results (61-70 of 176) with videos related to

Sort By:
Pageof 18
Clinical Lymphoma, Myeloma & Leukemia|June 15, 2013
Sequential lymphomas or clonally unrelated richter syndrome of chronic lymphocytic leukemia into mantle cell lymphomaPreetesh Jain, Xiuning Le, Ken H Young, et al.
American Journal of Nuclear Medicine and Molecular Imaging|September 13, 2021
Computer-aided detection of mantle cell lymphoma on <sup>18</sup>F-FDG PET/CT using a deep learning convolutional neural networkZijian Zhou, Preetesh Jain, Yang Lu, et al.
American Journal of Hematology|June 25, 2016
Mixed angioinvasive exserohilum and scedosporium infection in a patient with AMLPreetesh Jain, Priyadharsini Nagarajan, Parikshit Prayag, et al.
Haematologica|April 11, 2020
<i>MYC</i> rearrangement but not extra <i>MYC</i> copies is an independent prognostic factor in patients with mantle cell lymphomaLifu Wang, Guilin Tang, L Jeffrey Medeiros, et al.
American Journal of Hematology|September 28, 2016
PET-positive lymphadenopathy in CLL-Not always Richter transformationNaveen Pemmaraju, Preetesh Jain, L Jeffrey Medeiros, et al.
Blood|January 10, 2015
Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinibPreetesh Jain, Michael Keating, William Wierda, et al.
Cancer|February 8, 2017
Long-term outcomes for patients with chronic lymphocytic leukemia who discontinue ibrutinibPreetesh Jain, Philip A Thompson, Michael Keating, et al.
Blood Cancer Journal|February 16, 2023
Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutationsYuxuan Che, Yang Liu, Yixin Yao, et al.
Human Pathology|March 9, 2024
TP53 mutation is frequent in mantle cell lymphoma with EZH2 expression and have dismal outcome when both are presentDo Hwan Kim, Saima Siddiqui, Preetesh Jain, et al.
Blood Cancer Journal|April 8, 2026
Correction: Exploiting PRMT5 as a target for combination therapy in mantle cell lymphoma characterized by frequent ATM and TP53 mutationsYuxuan Che, Yang Liu, Yixin Yao, et al.
Pageof 18